Halozyme Therapeutics (HALO) Shares Repurchased (2019 - 2025)
Historic Shares Repurchased for Halozyme Therapeutics (HALO) over the last 7 years, with Q3 2025 value amounting to $38.9 million.
- Halozyme Therapeutics' Shares Repurchased changed N/A to $38.9 million in Q3 2025 from the same period last year, while for Dec 2025 it was $288.9 million, marking a year-over-year increase of 1555.32%. This contributed to the annual value of $342.4 million for FY2025, which is 3694.88% up from last year.
- Halozyme Therapeutics' Shares Repurchased amounted to $38.9 million in Q3 2025.
- Over the past 5 years, Halozyme Therapeutics' Shares Repurchased peaked at $252.3 million during Q4 2023, and registered a low of $1000.0 during Q4 2022.
- For the 5-year period, Halozyme Therapeutics' Shares Repurchased averaged around $123.1 million, with its median value being $113.1 million (2021).
- In the last 5 years, Halozyme Therapeutics' Shares Repurchased tumbled by 9999.93% in 2022 and then skyrocketed by 2522990000.0% in 2023.
- Quarter analysis of 5 years shows Halozyme Therapeutics' Shares Repurchased stood at $150.0 million in 2021, then tumbled by 100.0% to $1000.0 in 2022, then surged by 25229900.0% to $252.3 million in 2023, then dropped by 0.91% to $250.0 million in 2024, then plummeted by 84.45% to $38.9 million in 2025.
- Its Shares Repurchased stands at $38.9 million for Q3 2025, versus $250.0 million for Q4 2024 and $252.3 million for Q4 2023.